Novartis / Molecular Partners with Phase 2 success of Covid-19 drug
By Ed Frankl
ZURICH (Dow Jones) – The Swiss companies Novartis and Molecular Partners have published positive data on their antiviral Covid-19 drug Ensovibep and will apply for accelerated approval worldwide.
Novartis announced that a Phase 2 study of 407 patients who received a single intravenous dose of Ensovibep showed a 78 percent reduction in Covid-19-related hospital or emergency admissions compared to a placebo and an improvement in the time to for clinical recovery.
The Ensovibep treatment offers protection against the previously identified dangerous virus variants, including Omikron, according to the Basel-based drug manufacturer.
Novartis also announced that the group will exercise its option and pay 150 million Swiss francs to license Ensovibep from Molecular Partners and accelerate production.
In addition, the company plans to apply for accelerated approvals worldwide, initially through emergency approval from the U.S. Food and Drug Administration.
If approved, Ensovibep will be the first multi-specific antiviral molecule for the treatment of Covid-19, according to Novartis. The partner Molecular Partners AG is a biopharmaceutical company based in Zurich.
Contact the author :[email protected]
(END) Dow Jones Newswires
January 10, 2022 02:05 ET (07:05 GMT)